Skip to main content
Springer Nature Link
Log in

Risk Factors for Hepatocellular Carcinoma Among Chronic Hepatitis C Patients Treated with Interferon

  • Conference paper
HCV and Related Liver Diseases

  • 103 Accesses

  • 1 Citation

Abstract

In Japan, the incidence of hepatocellular carcinoma (HCC) has been increasing over the last 30 years, and epidemiological surveys have shown that as a causative agent, hepatitis C virus (HCV) is more common than hepatitis B virus (HBV). Chronic hepatitis C has been demonstrated to evolve to cirrhosis and HCC [1–3]. The HCC occurrence rate in cirrhotic patients with anti-HCV has been reported to increase steadily with a yearly incidence of 1.4%–7% [4–6]. Thus, a majority of cases with chronic HCV infection progress slowly to liver cirrhosis and HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. DiBisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ (1991) Long-term clinical and histological follow-up of chronic posttransfusion hepatitis. Hepatology 14:969–974

    Article  CAS  Google Scholar 

  2. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nagano Y, Furuta S, et al (1990) Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma. Analysis by detection of antibody to hepatitis C virus. Hepatology 12:671–675

    CAS  Google Scholar 

  3. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M (1995) Incidence of hepatocellular carcinoma in chronic hepatitis B and C. A prospective study of 251 patients. Hepatology 21:650–655

    CAS  Google Scholar 

  4. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H, et al (1993) A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 18:47–53

    Article  PubMed  CAS  Google Scholar 

  5. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, et al (1997) Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112:463–472

    Article  PubMed  CAS  Google Scholar 

  6. Oka H, Kurioka N, Kim K, Kanno T, Kuroki T, Mizoguchi Y, Kobayashi K (1990) Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 12:680–687

    Article  PubMed  CAS  Google Scholar 

  7. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Rerrilo RP, Carey W, et al (1989) Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized controlled trial. N Engl J Med 321:1501–1506

    CAS  Google Scholar 

  8. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, et al (1989) Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double blind placebo-controlled trial. N Engl J Med 321:1506–1510

    Google Scholar 

  9. Hagiwara H, Hayashi N, Mita E, Ueda K, Takehara T, Kasahara A, Fusamoto H, et al (1992) Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-a. Hepatology 15:37–41

    Article  PubMed  CAS  Google Scholar 

  10. Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, Kamada T (1993) Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 104:877–883

    PubMed  CAS  Google Scholar 

  11. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, et al (1995) Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 21:291–297

    Article  PubMed  CAS  Google Scholar 

  12. Hiramatsu N, Hayashi N, Kasahara A, Hagiwara H, Takehara T, Haruna Y, Naito M, et al (1995) Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. J Hepatol 22:135–142

    Article  PubMed  CAS  Google Scholar 

  13. Hagiwara H, Hayashi N, Kasahara A, Oshita M, Katayama K, Kato M, Masuzawa M, et al (1996) Treatment with recombinant interferon-α 2a for patients with chronic hepatitis C: predictive factors for biochemical and virologic response. Scand J Gastroenterol 31:1021–1026

    Article  PubMed  CAS  Google Scholar 

  14. Kuzushita N, Hayashi N, Katayama K, Kanto T, Oshita M, Hagiwara H, Kasahara A, et al (1997) High levels of serum interleukin-10 are associated with a poor response to interferon treatment in patients with chronic hepatitis C. Scand J Gastroenterol 32:169–174

    Article  PubMed  CAS  Google Scholar 

  15. Kasahara A, Hayashi N, Mochizuki K, Oshita M, Katayama K, Kato M, Masuzawa M, et al (1997) Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response. J Hepatol 26:574–583

    CAS  Google Scholar 

  16. Yuki N, Hayashi N, Kasahara A, Hagiwara H, Takehara T, Oshita M, Katayama K, et al (1995) Pretreatment viral load and response to prolonged interferon-α course for chronic hepatitis C. J Hepatol 22:457–463

    Article  PubMed  CAS  Google Scholar 

  17. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, et al (1992) Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 73:673–679

    Article  PubMed  CAS  Google Scholar 

  18. Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, Yagi S, Tanaka S, Hasegawa A, Ohta N, et al (1994) Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 19:1347–1353

    Article  PubMed  CAS  Google Scholar 

  19. Lau YN, Davis G, Kniffen J, Qian K-P, Urdea MS, Chan CS, Mizokami M, et al (1993) Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 341:1501–1504

    Article  PubMed  CAS  Google Scholar 

  20. Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, Nakamura A, et al (1997) Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 113:558–566

    Article  PubMed  CAS  Google Scholar 

  21. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al (1981) Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431–435

    Article  PubMed  CAS  Google Scholar 

  22. Kasahara A, Hayashi N, Mochizuki K, et al. (1998) Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic Hepatitis C. Hepatology 27:1394–1402

    Article  PubMed  CAS  Google Scholar 

  23. Hagiwara H, Hayashi N, Mita E, Naito M, Kasahara A, Fusamoto H, Kamada T (1993) Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease. Hepatology 17:545–550

    Article  PubMed  CAS  Google Scholar 

  24. Jouet P, Roudot-Thoraval F, Dhumeaux D, Metreau JM (1994) Comparative efficacy of interferon alpha in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 106:686–690

    PubMed  CAS  Google Scholar 

  25. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, et al (1995) Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346:1051–1055

    Article  PubMed  CAS  Google Scholar 

  26. Mazzelia G, Accogli E, Sottili S, Festi G, Orsini M, Salzetta A, Novelli V, et al (1996) Alpha-interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 24:141–147

    Article  Google Scholar 

  27. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, et al (1993) Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328:1797–1801

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Medicine, Osaka University Hospital, 2-15 Yamada-oka, Suita, Osaka, 565-0871, Japan

    Akinori Kasahara

  2. First-Department of Medicine, Osaka University School of Medicine, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan

    Akinori Kasahara & Norio Hayashi

  3. First-Department of Medicine, Aichi Medical School, Yazako, Ohaza, Nagakute-cho, Aichi, 480-11, Japan

    Shinichi Kakumu

  4. Second-Department of Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-0802, Japan

    Kendo Kiyosawa

  5. First-Department of Medicine, Yamaguchi University School of Medicine, 1144 Kogushi, Ooaza, Ube, Yamaguchi, 755-0067, Japan

    Kiwamu Okita

Authors
  1. Akinori Kasahara
    View author publications

    Search author on:PubMed Google Scholar

  2. Norio Hayashi
    View author publications

    Search author on:PubMed Google Scholar

  3. Shinichi Kakumu
    View author publications

    Search author on:PubMed Google Scholar

  4. Kendo Kiyosawa
    View author publications

    Search author on:PubMed Google Scholar

  5. Kiwamu Okita
    View author publications

    Search author on:PubMed Google Scholar

Consortia

The Osaka Liver Disease Study Group

Editor information

Editors and Affiliations

  1. First Department of Internal Medicine, Yamaguchi University School of Medicine, Kogushi, Ube, Yamaguchi, 755-8505, Japan

    Kiwamu Okita M.D., Ph.D. (Professor and Chairman) (Professor and Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Tokyo

About this paper

Cite this paper

Kasahara, A., Hayashi, N., Kakumu, S., Kiyosawa, K., Okita, K., The Osaka Liver Disease Study Group. (1999). Risk Factors for Hepatocellular Carcinoma Among Chronic Hepatitis C Patients Treated with Interferon. In: Okita, K. (eds) HCV and Related Liver Diseases. Springer, Tokyo. https://doi.org/10.1007/978-4-431-68488-6_9

Download citation

  • DOI: https://doi.org/10.1007/978-4-431-68488-6_9

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-68490-9

  • Online ISBN: 978-4-431-68488-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics